Pipeline Watch: Phase III Starts For CCX168, ETC-1002 And COR-003
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
You may also be interested in...
Instead of helping raise a Series A, the Teva chairman and others acquire the preclinical company, convinced of its synthetic nanotech promise in immuno-oncology. Vifor and ChemoCentryx expand their orphan and renal disease collaboration, while Gilead out-licenses an addiction drug candidate.
Evotec has gained access to next-generation antisense technology through forging a strategic partnership with the small German biotech, Secarna, and they aim to make available a joint antisense pipeline of new therapeutic options for industry partners.
Boehringer Ingelheim’s sales were driven by Jardiance and Ofev in the first half of 2020, with contract manufacturing contributing with a 16% increase in sales; more details from the EMPEROR-Reduced Phase III study in heart failure are expected at this month’s European College of Cardiology meeting.